Literature DB >> 6425788

[Evaluation of the incidence of serological cross reactions between Legionella and Mycoplasma or Chlamydia].

N Bornstein, J Fleurette, S Bosshard, C Bouvet, D Thouvenot, M Aymard.   

Abstract

Because of the possible serological cross reactions frequently described in the literature between L. pneumophila and M. pneumoniae or between L. pneumophila and Chlamydia, we decided to determine their frequency with our sera and our own methods. The anti M. pneumoniae and Chlamydia antibodies were researched in 162 sera samples from 46 cases of legionellosis serologically diagnosed and in 51 sera from 26 hyperimmunised rabbits. Conversely, anti L. pneumophila antibodies were researched in 165 sera from mycoplasmosis (61) or chlamydiosis (25 cases). None of the sera from mycoplasmosis or chlamydiosis tested by IFA and MA had antilegionella antibodies. None of the rabbits' sera hyperimmunised with Legionella had anti M. pneumoniae or Chlamydia antibodies. On the contrary, by complement fixation and IFA, out of the 46 cases of legionellosis under study, 6 showed a seroconversion in M. pneumoniae and 2 in Chlamydia. The Ig class determination did not show IgM titers in 7 of these 8 sera. The mechanisms of these cross reactions are discussed: antigens and methods used, booster effect during legionellosis, concurrent mycoplasmosis or chlamydiosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425788

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  Pulmonary involvement in Mycoplasma pneumoniae infection in families.

Authors:  A Hanukoglu; S Hebroni; D Fried
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

2.  Pericardial effusion as the only manifestation of infection with Francisella tularensis: a case report.

Authors:  Cécile Landais; Pierre-Yves Levy; Gilbert Habib; Didier Raoult
Journal:  J Med Case Rep       Date:  2008-06-13

3.  Pontiac fever: an operational definition for epidemiological studies.

Authors:  Paul Tossa; Magali Deloge-Abarkan; Denis Zmirou-Navier; Philippe Hartemann; Laurence Mathieu
Journal:  BMC Public Health       Date:  2006-04-28       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.